María Angélica Rodríguez Fernández

Ms. María Angélica Rodríguez Fernández

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MFMaría Angélica Rodríguez Fernández
María Angélica Rodríguez Fernández
FFFabiola Estefanía Tristán Flores
Fabiola Estefanía Tristán Flores
DCDiana Casique-Aguirre
Diana Casique-Aguirre
MRMaría De la luz xochilt Negrete Rodríguez
María De la luz xochilt Negrete Rodríguez
JCJuan Antonio Cervantes-Montelongo
Juan Antonio Cervantes-Montelongo
Guillermo Antonio Silva-MartínezGuillermo Antonio Silva-Martínez
Guillermo Antonio Silva-Martínez
Cardiovascular disease remains the leading global cause of mortality, largely driven by atherosclerosis, a chronic inflammatory condition characterized by lipid accumulation and immune-cell infiltration in arterial walls. Macrophages play a central role by forming foam cells and secreting pro-atherogenic cytokines, such as TNF-α, IFN-γ, and IL-1β, which destabilize atherosclerotic plaques, expanding the lipid core and increasing the risk of thrombosis and ischemia. Despite the significant health burden of subclinical atherosclerosis, few targeted therapies exist. Current treatments, including monoclonal antibodies, are limited by high costs and immunosuppressive side effects, underscoring the urgent need for alternative therapeutic strategies. In this study, we employed in silico drug repositioning to identify multitarget inhibitors against TNF-α, IFN-γ, and IL-1β, leveraging a virtual screening of 2750 FDA-approved drugs followed by molecular dynamics simulations to assess the stability of selected cytokine–ligand complexes. This computational approach provides structural insights into potential inhibitors. Additionally, we highlight nutraceutical options, such as fatty acids (oleic, linoleic and eicosapentaenoic acid), which exhibited strong and stable interactions with key cytokine targets. Our study suggests that these bioactive compounds could serve as effective new therapeutic approaches for atherosclerosis.